BioTime to Present Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)

ALAMEDA, Calif.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24BTX&src=ctag" target="_blank"gt;$BTXlt;/agt; lt;a href="https://twitter.com/hashtag/AMD?src=hash" target="_blank"gt;#AMDlt;/agt;--BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced today that updated results from a Phase I/IIa clinical study of its lead product candidate, OpRegen®, a retinal pigment epithelium (RPE) cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy, will be presented at the 2019 Association for Research in Vis

Full Story →

BioTime to Present Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)

ALAMEDA, Calif.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24BTX&src=ctag" target="_blank"gt;$BTXlt;/agt; lt;a href="https://twitter.com/hashtag/AMD?src=hash" target="_blank"gt;#AMDlt;/agt;--BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced today that updated results from a Phase I/IIa clinical study of its lead product candidate, OpRegen®, a retinal pigment epithelium (RPE) cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy, will be presented at the 2019 Association for Research in Vis

Full Story →